CL2018001407A1 - Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer - Google Patents

Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer

Info

Publication number
CL2018001407A1
CL2018001407A1 CL2018001407A CL2018001407A CL2018001407A1 CL 2018001407 A1 CL2018001407 A1 CL 2018001407A1 CL 2018001407 A CL2018001407 A CL 2018001407A CL 2018001407 A CL2018001407 A CL 2018001407A CL 2018001407 A1 CL2018001407 A1 CL 2018001407A1
Authority
CL
Chile
Prior art keywords
ilo
hydrogen
metoxi
cancer
treatment
Prior art date
Application number
CL2018001407A
Other languages
English (en)
Inventor
Maurice Raymond Verschoyle Finlay
Mark David Charles
Johannes Wilhelmus Maria Nissink
Original Assignee
Astrazeneca Ab
Cancer Research Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Cancer Research Tech Ltd filed Critical Astrazeneca Ab
Publication of CL2018001407A1 publication Critical patent/CL2018001407A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

UN COMPUESTO DE FÓRMULA (I), O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO, EN LA QUE: Q PUEDE SER 1,2,4-TRIAZIN-3-ILO, PIRIDAZIN-3-ILO, 6-METILPIRIDAZIN-3-ILO, O 6-FLUOROPIRIDAZIN-3-ILO; R1 PUEDE SER HIDRÓGENO, METOXI, TRIFLUOROMETOXI, OXETAN-3-ILO, 3-FLUOROAZETIDIN-1-ILO, 3-METOXIAZETIDIN-1-ILO, O 3,3-DIFLUOROAZETIDIN-1-ILO; R2 PUEDE SER HIDRÓGENO O FLÚOR; R3 PUEDE SER HIDRÓGENO O METOXI; Y R4 PUEDE SER METOXI, ETOXI, O METOXIMETILO; CON LA CONDICIÓN DE QUE CUANDO R1 SEA HIDRÓGENO, METOXI O TRIFLUOROMETOXI, ENTONCES R3 NO SEA HIDRÓGENO, Y/O R4 ES METOXIMETILO. EL COMPUESTO DE FÓRMULA (I) PUEDE INHIBIR LA GLUTAMINASA, POR EJEMPLO, GLS1.
CL2018001407A 2015-11-30 2018-05-24 Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer CL2018001407A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562260789P 2015-11-30 2015-11-30

Publications (1)

Publication Number Publication Date
CL2018001407A1 true CL2018001407A1 (es) 2018-10-12

Family

ID=57485461

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018001407A CL2018001407A1 (es) 2015-11-30 2018-05-24 Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer

Country Status (23)

Country Link
US (3) US10323028B2 (es)
EP (1) EP3383873B1 (es)
JP (1) JP6999550B2 (es)
KR (1) KR20180083942A (es)
CN (1) CN108349966B (es)
AR (1) AR106874A1 (es)
AU (1) AU2016363718B2 (es)
BR (1) BR112018010806A2 (es)
CA (1) CA3005495C (es)
CL (1) CL2018001407A1 (es)
CO (1) CO2018006928A2 (es)
EA (1) EA201891241A1 (es)
ES (1) ES2914333T3 (es)
IL (1) IL259510A (es)
MX (1) MX2018006532A (es)
NI (1) NI201800064A (es)
PH (1) PH12018501131A1 (es)
RU (1) RU2018123714A (es)
SG (1) SG11201803810XA (es)
SV (1) SV2018005702A (es)
TN (1) TN2018000127A1 (es)
TW (1) TW201733587A (es)
WO (1) WO2017093299A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201520959D0 (en) 2015-11-27 2016-01-13 Astrazeneca Ab And Cancer Res Technology Ltd Bis-pyridazine compounds and their use in treating cancer
US10323028B2 (en) 2015-11-30 2019-06-18 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
US10040789B2 (en) * 2015-11-30 2018-08-07 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
US9938265B2 (en) * 2015-11-30 2018-04-10 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
WO2018228435A1 (zh) * 2017-06-13 2018-12-20 南京明德新药研发股份有限公司 作为gls1抑制剂的化合物
AU2019363115B2 (en) 2018-10-16 2021-12-09 Medshine Discovery Inc. Thiadiazole derivative and uses thereof as a GLS1 inhibitor
WO2025196446A1 (en) * 2024-03-22 2025-09-25 Sitryx Therapeutics Limited Thiadiazoles as glutaminase 1 inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451828B1 (en) * 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
EA026656B1 (ru) * 2011-11-21 2017-05-31 Калитера Байосайенсиз Инк. Гетероциклические ингибиторы глютаминазы
LT2920168T (lt) * 2012-11-16 2021-10-25 Calithera Biosciences, Inc. Heterociklinis gliutaminazės inhibitorius
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
CA2934700A1 (en) 2014-01-06 2015-07-09 Rhizen Pharmaceuticals Sa Glutaminase inhibitors
US20150258082A1 (en) * 2014-03-14 2015-09-17 Francesco Parlati Combination therapy with glutaminase inhibitors
GB201409624D0 (en) * 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
GB201520959D0 (en) 2015-11-27 2016-01-13 Astrazeneca Ab And Cancer Res Technology Ltd Bis-pyridazine compounds and their use in treating cancer
US10323028B2 (en) 2015-11-30 2019-06-18 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
US10040789B2 (en) 2015-11-30 2018-08-07 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
US9938265B2 (en) * 2015-11-30 2018-04-10 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer

Also Published As

Publication number Publication date
CO2018006928A2 (es) 2018-10-10
WO2017093299A1 (en) 2017-06-08
SV2018005702A (es) 2018-11-27
SG11201803810XA (en) 2018-06-28
RU2018123714A (ru) 2020-01-09
EP3383873A1 (en) 2018-10-10
PH12018501131A1 (en) 2019-01-21
US20210246131A1 (en) 2021-08-12
AR106874A1 (es) 2018-02-28
TN2018000127A1 (en) 2019-10-04
US10323028B2 (en) 2019-06-18
ES2914333T3 (es) 2022-06-09
MX2018006532A (es) 2019-05-15
US20170152255A1 (en) 2017-06-01
BR112018010806A2 (pt) 2018-11-27
AU2016363718B2 (en) 2019-11-14
IL259510A (en) 2018-07-31
KR20180083942A (ko) 2018-07-23
US11753405B2 (en) 2023-09-12
TW201733587A (zh) 2017-10-01
CN108349966A (zh) 2018-07-31
US20190389853A1 (en) 2019-12-26
AU2016363718A1 (en) 2018-07-12
CN108349966B (zh) 2022-02-15
CA3005495A1 (en) 2017-06-08
CA3005495C (en) 2023-12-12
EP3383873B1 (en) 2022-03-09
JP2018535986A (ja) 2018-12-06
EA201891241A1 (ru) 2019-01-31
NI201800064A (es) 2018-10-18
JP6999550B2 (ja) 2022-02-10
US10981904B2 (en) 2021-04-20

Similar Documents

Publication Publication Date Title
SV2018005702A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
MX2023011675A (es) Beta-hidroxietilaminas heteroaril sustituidas para su uso en el tratamiento de hiperglucemia.
ECSP19042682A (es) Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes
CL2017001209A1 (es) Inhibidor de cinasa aurora a
CL2017000240A1 (es) Compuestos activos hacia bromodominios
MY186133A (en) Tgf-? inhibitors
CL2017001488A1 (es) Benzamidas sustituidas con 1,3–tiazol–2–ilo
MX2023000418A (es) Fluorofenil beta-hidroxietilaminas y su uso en el tratamiento de la hiperglucemia.
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
MX388321B (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
AR103680A1 (es) Inhibidores selectivos de bace1
BR112018075736A2 (pt) composto de amida alfa e beta insaturado derivado de benzotriazol usado como inibidor de tgf-betar1
CL2018001408A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer
MX2018014080A (es) Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia.
JOP20200291A1 (ar) معدلات التعبير عن apol1
AR112102A1 (es) Tinostamustina para utilizar en el tratamiento de cáncer de ovario
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
MX377172B (es) Formulacion de combinacion de tesofensina y betabloqueante
CL2017002960A1 (es) Compuesto para la profilaxis o el tratamiento de daño al órgano
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
AR112144A1 (es) Compuestos para el tratamiento del sarcoma
SV2018005713A (es) Compuestos de isoindol
EA201691566A1 (ru) Применение производных пиридазина для предупреждения или лечения атаксического синдрома
CL2022001353A1 (es) Inhibidores de egfr
CL2019002025A1 (es) Derivados de pirrolotriazina como inhibidor de cinasas.